- Date: March 30, 2017
25 April, second intermediate deadline for proposals to carry out high-quality scientific projects under the Horizon 2020 programme. The final deadline for submission is 5 September, 5:00 p.m. (local time in Brussels). For the first intermediate deadline of this call (19 January 2017), a total of 124 proposals were submitted.
The European Union concentrates much of its research and innovation activities under the framework programme called Horizon 2020, with a budget of almost €80 billion in funding available for 2014-2020. Its main function is to support frontier research, interdisciplinary proposals, and pioneering ideas in new and emerging fields that introduce unconventional and innovative approaches. Its mission is to encourage the highest-quality research in Europe through competitive funding.
Horizon 2020 integrates, for the very first time, all phases starting from knowledge creation to the activities closest to the market: basic research, development of technologies, demonstration projects, pilot lines for manufacturing, social innovation, technology transfer, proof of concept, standardisation, support for pre-commercial procurement, venture capital, and guarantee schemes.
ERC Proof of Concept Grants for ERC grant holders who want to check the market and/or innovation potential of research results from ERC-projects -up to 150,000 euro for a period of 12 months.
The programme’s website:
April 21, 2017
Managers of the top venture capital funds took part in the round table entitled “Alternativas en tu negocio (Alternatives for Your Business)” to share their personal views and the success stories that they have witnessed while working at their companies.
April 18, 2017
The biomedical company has signed a contract worth €320,000 with the Servier Research Institute for biomarker discovery tasks. Pangaea expects that the contract will be performed “gradually and completely” throughout the year.
April 03, 2017
The project will be able to diagnose endometrial cancer by performing a simple test based on the presence of two proteins in endometrial fluid. This is the fourth most common type of cancer in women.